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Precis: This study presents the first comprehensive assessment of access to prostate cancer care. 
We found that while access was positively correlated with higher overall perceived quality of 
care and better doctor-patient communication, it did not appear to explain observed racial 
differences. 
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ABSTRACT 
Background: Racial disparities in prostate cancer treatment and outcomes are widespread and 
poorly understood.  We sought to determine whether access to care, measured across multiple 
dimensions, contributed to racial differences in prostate cancer. 
Methods: The Philadelphia Area Prostate Cancer Access Study (P2 Access) included 2374 men 
diagnosed with localized prostate cancer in 2012-2014.  Men were surveyed to assess their 
experiences accessing care (response rate 51.1%).  We determined appointment availability at 
151 urology practices using simulated patient calls and calculated travel distances using 
geospatial techniques. We used multivariable logistic regression models to determine the 
association between five different domains of access—availability, accessibility, 
accommodation, affordability, and acceptability—and receipt of treatment, perceived quality of 
care, and doctor-patient communication. 
Results: There were 1907 non-Hispanic white and 394 black men in our cohort.  Overall, 85% of 
men received definitive treatment with no differences by race.  Black men were less likely to 
report high quality of care (69% vs 81%, p<0.001) and good doctor-patient communication than 
white men (60% vs 71%, p<0.001).  In adjusted models, none of the five domains of access were 
associated with definitive treatment overall or with radical prostatectomy.  All access domains 
were associated with perceived quality of care and communication, though these domains did not 
mediate racial disparities.  
Conclusions: This study presents the first comprehensive assessment of prostate cancer access, 
treatment, and patient experience, showing that while access was related to overall perceived 
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quality of care and better doctor-patient communication, it did not appear to explain observed 
racial differences. 
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INTRODUCTION 
Racial disparities in cancer treatment are well described but poorly understood. An 
estimated 161,360 men will be diagnosed with prostate cancer in 2016 with 26,730 dying of the 
disease1. Black men are more likely to be diagnosed with prostate cancer2 and more than twice as 
likely to die from the disease compared to white men3.  Additionally, black men are less likely to 
receive definitive treatment overall4 and experience lower quality of care5.  
Access to care may be an important—and potentially modifiable factor—contributing to 
racial disparities in cancer treatment and outcomes.  The leading definition of access, developed 
by Aday and Andersen6-8, defines access as “those dimensions which describe the potential and 
actual entry of a given population group to the health care delivery system.” Prior research on 
access to cancer care has focused primarily on cost- and travel-related barriers facing 
underserved populations9-13.  These studies have generally found that patients experiencing cost 
barriers have worse cancer outcomes, and patients that travel further are more likely to be 
diagnosed with later stage disease, have worse prognoses, and receive less definitive 
treatment10,11,14. Multiple other factors can also influence access, including the ability to get to an 
appointment, office waiting time, and cultural norms of providers and patients15.  To our 
knowledge, these factors have not been examined in combination to create a more 
comprehensive picture of how access may influence racial disparities.  
Using both patient surveys and an inventory of urology practice attributes, we created 
spatial measures of geographic access where men could have accessed care as well as individual 
measures of the access men actually experienced.  We sought to 1) examine whether patient race 
is associated with access to prostate cancer care, 2) assess whether differences in access are 
associated with differences in treatment, perceived quality of care, and doctor-patient 
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communication, and 3) test whether access mediates racial disparities in these outcomes. We 
hypothesized that black men would experience greater difficulties accessing care which would be 
associated with lower odds of treatment. Because lower access may constrain choices, we further 
hypothesized that less access would be associated with lower reported perceived quality of care 
and doctor-patient communication.  
 
METHODS  
The Philadelphia Area Prostate Cancer Access Study (P2 Access) is a mixed method 
study of men diagnosed with localized prostate cancer in the greater Philadelphia region. The 
study was approved by the institutional review boards at the University of Pennsylvania and 
Johns Hopkins University. 
Data sources  
Pennsylvania Cancer Registry (PCR) data: PCR data was used to identify black and white 
men diagnosed with localized prostate cancer between January 2012 and December 2014 in the 
greater Philadelphia region.  The PCR data provides information on patient socio-demographics, 
cancer characteristics, treatment, and insurance at the time of diagnosis.    
Patient survey:  We surveyed men identified from the PCR between February 2014 and 
August 2015 to understand their experiences accessing cancer care.  Pilot testing was conducted 
with prostate cancer patients recruited from a university clinic to ensure comprehension of the 
items.  Men received up to two mailings of the survey followed by phone calls to remind non-
responders to complete the mailed survey and give them the opportunity to complete the survey 
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by telephone.  All recipients received a $2 incentive with the first mailed survey, followed by 
$15 mailed upon completion of thesurvey. The response rate for the survey was 51.1%.  Patients 
were geocoded to their home address using ArcGIS v10.2 (ESRI, Redlands, CA).  
Practice inventory and audit survey:  We obtained information on all urology and 
radiation on ology clinics in the Philadelphia area and all adjacent counties (25 total counties) 
using data from the National Provider Identifier database and SK&A’s proprietary commercial 
database.  For the audit survey, research assistants posed as schedulers from a primary care 
office and requested the next available appointment for a patient with private insurance with an 
elevated prostate specific antigen level16.  We linked patients to their primary urologist as 
identified in the survey; 96% of survey respondents were successfully linked. 
American Community Survey (ACS) data: ACS data from 2008-2012 was used for 
census tracts characteristics.   
Patient cohort 
Inclusion criteria for the patient survey included a new prostate cancer diagnosis (e.g., not 
secondary to another cancer and not a recurrence); adenocarcinoma histology; resident of eight 
specified counties within the Greater Philadelphia area (Berks, Bucks, Chester, Delaware, 
Lancaster, Lehigh, Montgomery, and Philadelphia); and black or white race as indicated in the 
PCR data. Of the 2437 men who responded to the survey, 63 were excluded because they had 
metastatic disease at the time of presentation (n=51), received chemotherapy for treatment (n=4), 
or had military insurance (Tricare and Veterans Administration n=8), as it may impact their 
choice set of providers. The final analytic sample included 2,374 men.  
Access measures 
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We included 12 measures of access grouped into the five domains developed by 
Penchansky and Thomas,17 updating them, based on pilot testing with cancer survivors and 
physicians (see Supplementary Table 1).  For each domain, we created a summary score by first 
adding the measures and then creating a dichotomous measure of low vs. high access.  Low 
access was defined as having at least 1 measure in a domain meeting measure-specific criteria 
for low access, versus higher access. 
(1) Availability describes the adequacy of supply.  Patients were asked, “When choosing 
your urologist, how much choice did you have based on: (a) “where you live?” and (b) “your 
insurance plan?”  We dichotomized responses as “a great deal of choice” versus “some choice,” 
“a little choice,” and “no choice.” For each patient, we calculated the number of urology 
practices within a 30-minute drive of their home address using ArcGIS Network Analyst.  We 
dichotomized this measure as those with the fewest number of clinics (lowest quartile) versus the 
upper three quartiles.  
(2) Accessibility defines the location of supply, taking into account factors such as 
transportation and travel. On a five-point scale, patients were asked how easy or difficult it was 
for them to get to their urologist’s office.  Responses were dichotomized as “easy” versus all 
other categories.  Respondents were also asked about how many minutes it took them to get their 
urologist’s office with responses dichotomized as those with the longest reported times (highest 
quartile) versus all others. 
(3) Accommodation refers to how the supply is organized to accept clients. We obtained 
time to a new appointment from results of the audit survey and dichotomized responses as the 
longest time to a new appointment (top quartile) versus the bottom three quartiles. From the 
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survey, on a five-point scale from easy to difficult, we asked patients how easy or difficult it was 
(1) “getting an appointment on a day and time that was convenient for you” and (2) “getting in 
touch with your urologist outside of an appointment (for example, calling your urologist if you 
had a question).”  Responses to both were dichotomized as easy versus all others.  Respondents 
were also asked “About how many minutes did you usually wait after arriving at your urologist’s 
office before you were seen by the urologist” with results dichotomized as the longest wait times 
(top quartile) versus the bottom three. 
(4) Affordability describes the costs relative to a person’s ability to pay.  We asked how 
easy or difficult (5-point scale) it was to get approval from your insurance company to see your 
urologist with responses dichotomized as easy versus all others.  We further asked “Since you 
were diagnosed with prostate cancer, was there a time you had a hard time affording your 
urologist’s bills?” Responses were either yes or no. 
(5) Acceptability indicates the clients’ attitudes relative to a client’s characteristic.  This 
was assessed through a single survey measure of “how would you rate the appearance of your 
urologist’s office?” on a five-point scale from poor to excellent with responses dichotomized as 
excellent versus less than excellent.   
Treatment 
Definitive treatment was classified as having either radical prostatectomy or radiotherapy 
(including external beam radiation therapy or seed brachytherapy) as abstracted from PCR.    
Perceived quality of care and doctor-patient communication 
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Perceived quality of care was assessed from the patient survey item: “Overall, how would 
you rate the quality of health care for your prostate cancer?” with responses ranging from poor to 
excellent on a five-point scale as previously described18.  We dichotomized answers as excellent 
versus all other categories. We included four previously validated measures from the patient 
survey on doctor-patient communication, which came from the Consumer Assessment of 
Healthcare Providers and Systems, based on whether the patient’s urologist explained things in a 
way that was easy to understand, listened carefully, showed respect, and spent enough time19.  
Items were answered on a 4-point scale (never, sometimes, usually, always).  Responses to each 
item were converted into binary indicators (always=1 vs. all others=0) and summed to create a 
composite measure that ranged from 0-4. Poor communication was defined as a composite score 
less than 4. 
Patient characteristics 
Patient socio-demographic characteristics from the survey included race/ethnicity, age, 
education, and marital status.  Survey data were also used to construct a validated mortality 
index based on age, BMI, tobacco use, comorbidity, and functional status20.  Insurance at the 
time of diagnosis, Gleason score, and clinical tumor stage were derived from PCR data.  We 
created risk categories based on National Comprehensive Cancer Network (NCCN) criteria 
classified as low, intermediate and high risk21. 
Neighborhood characteristics 
Neighborhood socioeconomic status was based on six ACS census tract variables 
including median household income and the percentage of:  adults older than 25 years with less 
than a high school education, unemployed males, households living in poverty, households 
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receiving public assistance, and female-headed households22. Population density was defined as 
the total population divided by area in square miles (log transformed for analyses).   
Statistical analysis 
To examine whether access was associated with patient race, we used chi-squared tests to 
compare the five access domains for white and black men. We then constructed multivariable 
logistic regression models adjusting for socio-demographic and neighborhood characteristics for 
each access domain with patient race as the primary predictor. We accounted for clustering at the 
census tract level using Generalized Estimating Equations (GEE) methodology23. Separate 
models were constructed for each access domain and results are presented as predicted 
probabilities. 
Next, we examined whether access was associated with receipt of definitive treatment 
overall and with radical prostatectomy.  We performed multivariable logistic regression models 
in which we included all access domains in the same model adjusting for patient socioeconomic 
and neighborhood characteristics and clinical factors (life expectancy, Gleason score, and 
clinical tumor stage) and accounting for clustering of patients within census tracts using GEE.  
We repeated the analyses for perceived quality of care and doctor-patient communication 
outcomes; however, in these models we also adjusted for receipt of definitive treatment.  We 
then assessed whether access measures mediate racial differences in these associations using the 
four-stage regression approach24.  Finally, in subgroup analyses, we examined the association 
between access and receipt of definitive treatment for men with NCCN low and 
intermediate/high risk disease.  For covariates with missing data, we used multiple imputation 
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via multiple chained equations, creating five imputed datasets.  Analyses were conducted in SAS 
software v9.4. 
 
RESULTS 
Of the 2374 men in our sample, 1907 were non-Hispanic white and 394 were non-
Hispanic black (Table 1).  Black men were slightly younger and more likely to have Medicaid 
insurance, lower income, and a high school education or less.  Overall, 71.4% had stage 1 
disease, though black men were more likely to have a Gleason score of 7 or higher (63.0% vs. 
56.2%). There were no differences by race in the receipt of definitive treatment overall or for 
radical prostatectomy alone.  Black men were significantly less likely to report high levels of 
perceived quality of care (69% vs 81%, p<0.001) and less likely to report good doctor-patient 
communication (60% vs 71%, p<0.001). 
Racial differences in access to prostate cancer care 
Comparing unadjusted measures of access between white and black men (Table 2), we 
find that black men reported less availability, including less choice based on where they lived 
(36.3% for black men vs 31.0% for white men, p<0.001) and less choice based on their insurance 
plan (35.0% vs 25.6%, p<0.001).  In contrast, black men tended to have more clinics within a 30-
minute drive (8.6% of black men in low access category vs 26.6% of white men, p<0.001). Black 
men reported less difficulty in getting to their doctor’s office (22.3% of black men reported 
difficulty vs 28.2% of white men, p=0.015), but similar travel times.  There were no significant 
differences in the four accommodation items except that black men reported more ease in getting 
a convenient appointment.  With affordability, black men reported greater difficulty getting 
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insurance approval (21.1% for black men vs 13.3% for white men, p<0.001) and affording 
medical bills (22.1% vs 7.5%, p<0.001).  We did not find any racial differences in the 
acceptability access domain.  In adjusted analyses, we did not observe black-white differences in 
any of the five access domains (Figure 1, full models shown in Supplementary Table 2).  
Association of access to care with outcomes 
None of the five access domains were associated with receipt of definitive treatment 
overall or with radical prostatectomy alone (Table 3).  In contrast, we found that worse access in 
each access domain was independently associated with both lower perceived quality of care and 
worse communication. For example, men with lower acceptability measures were approximately 
three times more likely to report lower perceived quality of care  (OR 2.81, 95%CI 2.16, 3.66) 
and worse doctor-patient communication (OR 3.08, 95%CI 2.49, 3.81).   In subgroup analyses, 
of men with NCCN low risk disease (Table 3), access was not associated with receipt of 
definitive treatment.  However, among men with higher risk disease, those with lower levels of 
accessibility had significantly lower odds of definitive treatment compared to men with higher 
levels of accessibility (OR 0.55, 95% CI 0.35, 0.85). 
Mediation of racial differences in care 
In unadjusted models, black men reported lower levels of perceived quality of care and 
worse doctor-patient communication with care (Supplementary Table 3).  Communication 
remained lower among black men compared to white men in adjusted models (OR 1.49, 95%CI 
1.03, 2.16).  We did not find evidence that differences in the access domains mediated racial 
differences in these outcomes.   
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DISCUSSION 
The results provide the first multidimensional picture of access to prostate cancer care, 
underscoring the importance of access to care and its limits with respect to understanding 
prostate cancer disparities.  Our study has three main findings.  First, contrary to our 
expectations, we did not observe significant black-white differences in access across multiple 
domains, after accounting for socioeconomic characteristics.  Second, lower access was not 
associated with differential rates of definitive treatment or with radical prostatectomy overall, 
though men with intermediate and high risk disease and lower accessibility were less likely to 
get definitive treatment. Less access across all access domains was associated with lower 
perceived quality of care and doctor-patient communication.  Third, racial differences in these 
outcomes were not mediated by access to care measures.    
While overall access measures did not differ by patient race in models adjusting for 
socioeconomic status, black men reported less availability based on where they lived.  In 
contrast, a geographically-constructed measure of availability (number of clinics within a 30 
minute drive) showed that black men tended to have a higher number of clinics.  The 
contradictory patterns based on self-report versus calculated measures suggest important 
discrepancies between potential and realized access for cancer care and underscoring how 
different approaches to measurement may lead to different results.   
Contrary to expectations, we did not find access domains to be associated with receipt of 
definitive treatment for localized prostate cancer.  However, one domain—lower accessibility—
was associated with definitive treatment of intermediate and high risk disease.  We would have 
anticipated that, because definitive treatment of low risk disease is more controversial, it would 
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have been more likely to be related to access.   The possibility that accessibility could be 
associated with under-treatment of higher risk disease warrants further investigation. 
  Multiple dimensions of access are associated with patients’ overall experience with 
cancer care including perceived quality of care and doctor-patient communication. The 
mechanisms underlying these findings warrant further investigation.  One possibility is that 
physicians in areas with lower access may feel less competitive pressure to improve 
communication and quality, or perhaps these providers disproportionately lack the appropriate, 
resources and training to improve on these measures.  Another possible explanation is that lower 
access may limit patients’ perceived or actual ability to change physicians with whom they were 
less satisfied and/or have poorer communication.  At the same time, access did not appear to 
mediate racial differences in these outcomes, raising the need to examine other factors, such as 
distrust in the health care system, to disentangle racial disparities. 
This study has several limitations.  First, our findings are susceptible to non-response 
bias, as white men were more likely than black men to respond to the P2 Access survey, as were 
men who received definitive treatment (Appendix Table 4).  Second, patient-reported measures 
may be subject to recall and social desirability bias. However, we are not certain of the direction 
of these biases or how it may impact our associations. Third, geographically-derived access 
measures are based on estimated drive times using patients’ home addresses as the starting 
location.  Patients may travel from other locations (e.g. work), experience different traffic 
conditions, and use alternative modes of transportation.  Fourth, the use of a simulated scheduler 
from a doctor’s office may yield a higher rate of appointments than if the patient or family 
member tried to make an appointment.  Furthermore, whether the referral comes from within or 
outside the same health care system and potentially the type of health care system of the 
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appointment scheduler may affect appointment acquisition for actual patients.   Fifth, we did not 
examine whether there were differences in the next available appointment for patients with 
specific types of insurance.  Also, our data does not include measures that may help explain 
some of the observed associations, such as patient-physician race concordance which has been 
associated with communication25 and physician’s patient volume which has been linked with 
surgical outcomes.26 Sixth, we focused on accessibility to urologists rather than radiation 
oncologists.  With black men more likely to receive radiation therapy, examining racial 
differences in access to different cancer specialists is an important next step. Finally, data was 
obtained for one geographic area, which may limit generalizability.  The study area includes 5.3 
million residents across urban and suburban locales with 29% of the area’s population being 
nonwhite.  Focusing on a single area allowed us to obtain a large sample size and a rich 
collection of data sources; however, results may be different in more rural areas or with respect 
to different cancers where there may be greater clinical urgency to treat cancers quickly. 
The recent expansion of health insurance coverage offers the promise of improving 
access by helping to address financial barriers. However, access also requires addressing non–
financial access barriers.  Our results suggest that for men with prostate cancer, less access 
across a number of domains is associated with lower patient-reported quality of doctor-patient 
communication and perceived quality of care.  Measuring and addressing various dimensions of 
access can identify modifiable factors associated with improved outcomes but may still be 
insufficient for addressing racial differences in prostate cancer care delivery. 
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FIGURE LEGENDS 
Figure 1. Predicted Probability of Reporting Lower Access to Care by Race.  
*Predicted probability (with standard deviation) from logistic GEE model adjusting for patient 
age, income, education, insurance coverage, marital status, as well as census tract SES and 
natural log-transformed population density. 
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Table 1. Descriptive Statistics of the Sample; Overall and by Race* 
*Race stratified columns exclude 73 men of Hispanic ethnicity or not white or black race. †Certain characteristics 
do not add up to 100% due to missing data. 
 
 
Characteristic† 
Overall 
Non-Hispanic 
White 
Non-Hispanic 
Black p-value 
N=2374 N=1907 N=394 
Age (years) <.001 
   <60 699 (29.4%) 517 (27.1%) 155 (39.3%)   
   60-64 508 (21.4%) 401 (21.0%) 89 (22.6%)   
   65-69 558 (23.5%) 472 (24.8%) 72 (18.3%)   
   70-74 347 (14.6%) 288 (15.1%) 48 (12.2%)   
   ≥75 262 (11.0%) 229 (12.0%) 30 (7.6%)   
Insurance <.001 
   Private 1309 (55.1%) 1070 (56.1%) 205 (52.0%)   
   Medicaid 72 (3.0%) 23 (1.2%) 42 (10.7%)   
   Medicare 956 (40.3%) 787 (41.3%) 138 (35.0%)   
Income <.001 
   <$25,000 306 (12.9%) 130 (6.8%) 152 (38.6%)   
   $25,000-49,999 389 (16.4%) 306 (16.1%) 76 (19.3%)   
   $50,000-74,999 365 (15.4%) 309 (16.2%) 44 (11.2%)   
   $75,000-99,999 313 (13.2%) 261 (13.7%) 45 (11.4%)   
   ≥$100,000 740 (31.2%) 691 (36.2%) 37 (9.4%)   
Education <.001 
   Some high school 176 (7.4%) 91 (4.8%) 68 (17.3%)   
   High school grad/GED 588 (24.8%) 437 (22.9%) 134 (34.0%)   
   Some college/2-year degree 509 (21.4%) 390 (20.5%) 101 (25.6%)   
   4-year college grad 381 (16.1%) 336 (17.6%) 37 (9.4%)   
   >4-year college degree 665 (28.0%) 609 (31.9%) 45 (11.4%)   
Marital Status <.001 
   Married 1895 (79.8%) 1603 (84.1%) 232 (58.9%)   
   Not married 444 (18.7%) 282 (14.8%) 149 (37.8%)   
Life Expectancy <.001 
   <25% mortality 739 (31.1%) 606 (31.8%) 110 (27.9%)   
   25-50% mortality 743 (31.3%) 639 (33.5%) 85 (21.6%)   
   50-75% mortality 532 (22.4%) 409 (21.5%) 108 (27.4%)   
   >75% mortality 216 (9.1%) 154 (8.1%) 52 (13.2%)   
Gleason Score 0.02 
   <7 940 (39.6%) 776 (40.7%) 131 (33.3%)   
   7 946 (39.9%) 741 (38.9%) 175 (44.4%)   
   >7 413 (17.4%) 331 (17.4%) 73 (18.5%)   
Clinical Tumor Stage 0.10 
   Stage 1 1695 (71.4%) 1346 (70.6%) 294 (74.6%)   
   Stage 2 573 (24.1%) 477 (25.0%) 79 (20.1%)   
   Stage 3 58 (2.4%) 45 (2.4%) 12 (3.1%)   
Receipt of Definitive 
Treatment 
0.09 
   Yes 2028 (85.4%) 1639 (90.0%) 330 (83.8%)   
   No 295 (12.4%) 224 (11.8%) 59 (15.0%)   
Radical Prostatectomy    0.40 
   Yes 1223 (51.5%) 992 (52.0%) 192 (49.8%)  
   No 1053 (44.4%) 838 (43.9%) 182 (46.2%)  
Communication <.001 
   Good 1631 (68.7%) 1346 (70.6%) 237 (60.2%)   
   Not Good 718 (30.2%) 542 (28.4%) 152 (38.6%)   
Perceived Quality <.001 
   Good 1860 (78.4%) 1538 (80.7%) 270 (68.5%)   
   Not Good 438 (18.5%) 310 (16.3%) 111 (28.2%)   
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Table 2. Comparison of Access Measures and Domains by Race 
 
 
 
 
 
 
  
 
Non-Hispanic 
White  
Non-Hispanic 
Black  p-value 
N=1907 N=394 
Availability 
   Less choice based on where you live 591 (31.0%) 143 (36.3%) <.001 
   Less choice based on your insurance plan 488 (25.6%) 138 (35.0%) <.001 
   Lower geographic availability 508 (26.6%) 34 (8.6%) <.001 
   Summary Score for Lower Availability 835 (43.8%) 157 (39.9%) 0.55 
Accessibility 
   Less easy getting to your MD’s office 538 (28.2%) 88 (22.3%) 0.02 
   Self-reported longer time to get to MD  431 (22.6%) 73 (18.5%) 0.19 
   Summary Score for Lower Accessibility 687 (36.0%) 119 (30.2%) 0.12 
Accommodation 
   Longer time to a new appointment 289 (15.2%) 63 (16.0%) 0.45 
   Less easy to get a convenient appointment 698 (36.6%) 120 (30.5%) 0.02 
   Longer wait to be seen  381 (20.0%) 88 (22.3%) 0.25 
   Less easy getting in touch outside an appointment  851 (44.6%) 161 (40.9%) 0.13 
   Summary Score for Lower Accommodation 921 (48.3%) 174 (44.2%) 0.26 
Affordability 
   Less easy getting insurance approval 254 (13.3%) 83 (21.1%) <.001 
   Hard time affording bills 143 (7.5%) 87 (22.1%) <.001 
   Summary Score for Lower Affordability 351 (18.4%) 123 (31.2%) <.001 
Acceptability  
   Less than excellent office appearance 607 (31.8%) 119 (30.2%) 0.55 
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Table 3. Adjusted Relationship between Access Domains and Treatment, Perceived Quality, and Communication; OR (95%CI)* 
 
*Models simultaneously included all 5 access domains and adjust for patient age, race, income, education, insurance coverage, marital status, 
Gleason score, clinical tumor stage, life expectancy, as well as census tract SES and natural log-transformed population density. For perceived 
quality and communication analyses, receipt of definitive treatment is also included as a covariate. Bold indicates statistical significant at p<0.05. 
 
 Outcome 
 Receipt of Definitive Treatment    
 
Overall 
Low Risk Only 
(N=622) 
Not Low Risk 
(N=1423) 
Receipt of 
Surgery 
Lower Perceived 
Quality 
Worse 
Communication 
Higher 
availability Ref Ref Ref Ref Ref Ref 
Lower 0.97 (0.72, 1.31) 1.34 (0.87, 2.05) 0.83 (0.49, 1.39) 1.12 (0.89, 1.40) 1.47 (1.14, 1.89) 1.56 (1.26, 1.94) 
Higher 
accessibility Ref Ref Ref Ref Ref Ref 
Lower 0.76 (0.56, 1.04) 0.55 (0.35, 0.85) 0.96 (0.58, 1.57) 1.22 (0.99, 1.49) 1.59 (1.23, 2.06) 1.26 (1.01, 1.57) 
Higher 
accommodation Ref Ref Ref Ref Ref Ref 
Lower 0.81 (0.58, 1.13) 0.94 (0.56, 1.56) 1.01 (0.54, 1.89) 0.78 (0.60, 1.00) 2.10 (1.51, 2.92) 2.96 (2.30, 3.81) 
Higher 
affordability Ref Ref Ref Ref Ref Ref 
Lower 1.06 (0.73, 1.55) 1.08 (0.66, 1.77) 1.26 (0.69, 2.30) 0.85 (0.66, 1.09) 1.57 (1.19, 2.08) 1.48 (1.15, 1.90) 
Higher 
acceptability Ref Ref Ref Ref Ref Ref 
Lower 1.10 (0.81, 1.49) 1.58 (0.97, 2.55) 0.78 (0.45, 1.34) 0.99 (0.80, 1.22) 3.35 (2.61, 4.30) 3.40 (2.77, 4.18) 
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Supplementary Table 1. Comparison of measures used by Penchansky and Thomas and current study to define five dimensions of access 
Domain Measures used by Penchasky and 
Thomas 
Current study question Response options Coding of higher versus 
lower access 
AVAILABILITY.  
Adequacy of supply 
• All things considered, how much 
confidence do you have in being able to 
get good medical care for you and your 
family when you need it?  
• How satisfied are you with your ability 
to find one good doctor to treat the 
whole family? 
• How satisfied are you with your 
knowledge of where to get health care? 
• How satisfied are you with your ability 
to get medical care in an emergency? 
1. When choosing your urologist, how 
much choice did you have based on 
where you live? 
No choice, A little choice, 
Some choice, A great deal 
of choice 
Less choice vs. A great deal of 
choice 
2. When choosing your urologist, how 
much choice did you have based on our 
insurance plan? 
No choice, A little choice, 
Some choice, A great deal 
of choice 
Less choice vs. A great deal of 
choice 
3. Geographic availability using GIS-
calculated travel times. 
Number of practices within 
30 minute radius 
Less than Q1 vs. Greater than or 
equal to Q1 
ACCESSIBILITY. 
Location of supply and 
location of clients, 
taking into account 
transportation, travel 
time, distance, and cost 
• How satisfied are you with how 
convenient your physician’s offices are 
to your home?  
• How difficult is it for you to get to your 
physician’s office? 
4. Getting to your urologist’s office. Difficult (1) to Easy (5) Less easy vs. Easy 
5. Time to get to urologists office. Minutes Greater than Q3 vs. Less than or 
equal to Q3 
ACCOMMODATION. 
Manner in which the 
supply is organized to 
accept clients 
 
 
 
• How satisfied are you with how long 
you have to wait to get an appointment?  
• How satisfied are you with how 
convenient physicians’ office hours are? 
• How satisfied are you with how long 
you have to wait in the waiting room? 
• How satisfied are you with how easy it 
is to get in touch with your physician(s)? 
6. Time to new appointment from audit 
survey. 
Days to new appointment Greater than Q3 vs. Less than or 
equal to Q3 
7. Getting an appointment on a day and 
time that was convenient for you. 
Difficult (1) to Easy (5) Less easy vs. Easy 
8. About how many minutes did you 
usually wait after arriving at your 
urologist’s office before you were seen 
by the urologist?   
Minutes Greater than Q3 vs. Less than or 
equal to Q3 
 
9. Getting in touch with your urologist 
outside of an appointment (for 
example, calling your urologist if you 
had a question). 
Difficult (1) to Easy (5) Less easy vs. Easy 
AFFORDABILITY. 
Insurance, income 
• How satisfied are you with your health 
insurance? 
• How satisfied are you with the doctors’ 
prices? 
• How satisfied are you with how soon 
you need to pay the bill? 
10. Getting approval from your insurance 
company to see your urologist. 
Difficult (1) to Easy (5) Less easy vs. Easy 
11. Since you were diagnosed with 
prostate cancer, was there a time you 
had a hard time affording your 
urologist’s bills? 
Yes/No Yes vs. No 
ACCEPTABILITY. 
Clients’ attitudes about 
personal and practice 
characteristics 
• How satisfied are you with the 
appearance of the doctor’s offices? 
• How satisfied are you with the 
neighborhoods their offices are in?  
• How satisfied are you with the other 
patients you usually see at the doctors’ 
offices? 
12. On a scale of 1 to 5, how would you 
rate the appearance of your urologist’s 
office? 
Poor (1) to Excellent (5) Less Excellent vs. Excellent 
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Supplementary Table 2. Adjusted Association between Demographic Characteristics and Access Domains (Odds Ratios and 95% Confidence Intervals)* 
Characteristic Availability Accessibility Accommodation Affordability Acceptability 
Race/Ethnicity      
   Non-Hispanic White Ref Ref Ref Ref Ref 
   Non-Hispanic Black 0.81 (0.59, 1.13) 0.99 (0.73, 1.35) 0.74 (0.54, 1.02) 1.12 (0.79, 1.60) 1.29 (0.96, 1.73) 
   Hispanic 1.22 (0.60, 2.49) 0.83 (0.44, 1.59) 0.62 (0.30, 1.26) 1.35 (0.70, 2.61) 0.98 (0.45, 2.14) 
   Non-Hispanic Other 0.69 (0.28, 1.71) 0.63 (0.24, 1.66) 0.90 (0.40, 2.07) 0.80 (0.27, 2.39) 0.85 (0.34, 2.09) 
Income      
   <25,000 Ref Ref Ref Ref Ref 
   25,000-49,999 1.04 (0.73, 1.48) 0.62 (0.43, 0.88) 0.77 (0.53, 1.13) 0.60 (0.41, 0.86) 1.04 (0.72, 1.50) 
   50,000-74,999 0.88 (0.60, 1.28) 0.55 (0.38, 0.81) 0.60 (0.41, 0.86) 0.40 (0.27, 0.60) 0.96 (0.63, 1.47) 
   75,000-99,999 0.71 (0.47, 1.05) 0.56 (0.38, 0.84) 0.58 (0.38, 0.90) 0.28 (0.18, 0.44) 1.09 (0.71, 1.65) 
   >100,000 0.64 (0.43, 0.94) 0.84 (0.55, 1.27) 0.78 (0.51, 1.19) 0.25 (0.16, 0.39) 1.16 (0.77, 1.76) 
Education      
   Some high school Ref Ref Ref Ref Ref 
   High school grad or GED 1.01 (0.66, 1.53) 0.93 (0.62, 1.39) 1.17 (0.79, 1.74) 1.05 (0.65, 1.68) 0.95 (0.62, 1.45) 
   Some college or 2-year degree 0.88 (0.56, 1.38) 1.09 (0.72, 1.64) 1.53 (1.03, 2.27) 1.47 (0.92, 2.36) 1.00 (0.66, 1.52) 
   4-year college grad 0.85 (0.53, 1.36) 1.25 (0.80, 1.93) 1.84 (1.18, 2.88) 1.34 (0.80, 2.26) 1.45 (0.92, 2.29) 
   More than 4-year college degree 0.86 (0.54, 1.37) 1.64 (1.06, 2.54) 1.86 (1.22, 2.85) 1.69 (1.00, 2.84) 1.82 (1.18, 2.83) 
Age      
   Age <60 Ref Ref Ref Ref Ref 
   Age 60-64 0.90 (0.70, 1.17) 0.82 (0.63, 1.05) 0.83 (0.63, 1.09) 0.65 (0.49, 0.86) 0.78 (0.60, 1.00) 
   Age 65-70 0.92 (0.70, 1.21) 0.62 (0.46, 0.85) 0.75 (0.56, 1.01) 0.59 (0.41, 0.84) 0.90 (0.65, 1.23) 
   Age 70-74 0.78 (0.56, 1.08) 0.65 (0.46, 0.92) 0.76 (0.55, 1.05) 0.63 (0.42, 0.94) 0.78 (0.54, 1.13) 
   Age >=75 0.96 (0.67, 1.37) 0.67 (0.45, 1.01) 0.72 (0.48, 1.07) 0.64 (0.40, 1.01) 0.81 (0.54, 1.20) 
Insurance      
   Private Ref Ref Ref Ref Ref 
   Medicaid 1.31 (0.63, 2.72) 1.40 (0.82, 2.40) 0.61 (0.35, 1.07) 0.68 (0.37, 1.23) 0.99 (0.56, 1.78) 
   Medicare 0.67 (0.52, 0.86) 1.06 (0.81, 1.38) 0.93 (0.72, 1.20) 0.48 (0.35, 0.64) 0.79 (0.60, 1.04) 
Marital Status      
   Yes Ref Ref Ref Ref Ref 
   No 1.24 (0.93, 1.65) 0.96 (0.74, 1.23) 0.96 (0.75, 1.24) 1.00 (0.74, 1.35) 0.97 (0.75, 1.26) 
Population Density 0.58 (0.52, 0.65) 0.83 (0.76, 0.90) 1.05 (0.96, 1.14) 1.01 (0.91, 1.11) 1.00 (0.92, 1.08) 
SES Index 0.96 (0.95, 0.97) 1.00 (0.99, 1.01) 1.00 (0.99, 1.01) 0.99 (0.98, 1.00) 1.01 (1.00, 1.01) 
*Separate models were run for each domain. Bold indicates statistically significant at p<0.05.
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Supplementary Table 3. Unadjusted and Adjusted Associations between Race and Treatment, 
Satisfaction, and Communication (Odds Ratios and 95% Confidence Intervals) 
 
Outcome 
 
 
Receipt of 
Definitive 
Treatment 
Receipt of 
Surgery 
Lower 
Satisfaction with 
Care 
Worse 
Communication 
Unadjusted model     
   Non-Hispanic White Ref Ref Ref Ref 
   Non-Hispanic Black 0.77 (0.57, 1.05) 0.92 (0.74, 1.16) 2.13 (1.66, 2.73) 1.61 (1.28, 2.02) 
   Hispanic 1.03 (0.41, 2.60) 1.09 (0.58, 2.04) 2.03 (1.07, 3.86) 1.68 (0.90, 3.10) 
   Other 0.36 (0.15, 0.88) 0.81 (0.38, 1.75) 0.72 (0.21, 2.50) 0.65 (0.24, 1.78) 
Adjusted models without 
access measures*  
 
  
   Non-Hispanic White Ref Ref Ref Ref 
   Non-Hispanic Black 0.89 (0.55, 1.43) 1.05 (0.77, 1.45) 1.51 (1.08, 2.12) 1.39 (1.03, 1.89) 
   Hispanic 1.29 (0.51, 3.29) 0.95 (0.45, 1.98) 1.40 (0.68, 2.89) 1.70 (0.91, 3.19) 
   Other 0.38 (0.15, 0.97) 0.79 (0.31, 2.02) 0.53 (0.15, 1.89) 0.57 (0.21, 1.57) 
Adjusted model with 
access measures*† 
   Non-Hispanic White 
 
 
Ref 
  
 
Ref 
 
 
Ref 
 
Ref 
   Non-Hispanic Black 0.86 (0.53, 1.41) 1.06 (0.76, 1.46) 1.51 (1.03, 2.22) 1.46 (1.01, 2.12) 
   Hispanic 1.26 (0.49, 3.24) 0.94 (0.45, 1.96) 1.54 (0.70, 3.35) 2.06 (1.01, 4.18) 
   Other 0.37 (0.14, 0.94) 0.79 (0.30, 2.08) 0.54 (0.13, 2.22) 0.56 (0.19, 1.65) 
*Models adjust for patient age, income, educational attainment, insurance coverage, marital status, 
Gleason score, clinical tumor stage, life expectancy, census tract SES and natural log-transformed 
population density. For satisfaction and communication analyses, treatment type is also included as a 
covariate. †Models additionally adjust for 5 access domains. Bold indicates statistically significant at 
p<0.05. 
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Supplementary Table 4. Demographic and clinical characteristics of  
responders vs. non-responders based on Pennsylvania Cancer Registry data 
 
 Responders Non-Responders  
Characteristic N=2386  N=2286 p-value 
 N (%) N (%)  
Age (years)     0.044 
   <60 704 (29.5) 712 (31.2)   
   60-64 511 (21.4) 492 (21.5)   
   65-69 559 (23.4) 464 (20.3)   
   70-74 349 (14.6) 323 (14.1)   
   ≥75 263 (11.0) 294 (12.9)   
   Missing 0 (0.0) 1 (0.0)   
Race/Ethnicity*     <0.0001 
   Non-Hispanic White 1850 (77.5) 1405 (61.5)   
   Non-Hispanic Black 391 (16.4) 691 (30.2)   
   Hispanic 32 (1.3) 88 (3.9)   
   Non-Hispanic Other 0 (0.0) 0 (0.0)   
   Missing 113 (4.7) 102 (4.5)   
Insurance     0.058 
   Private 1310 (54.9) 1198 (52.4)   
   Medicaid 73 (3.1) 102 (4.5)   
   Medicare 958 (40.2) 921 (40.3)   
   None/Other 19 (0.8) 20 (0.9)   
   Missing 26 (1.1) 45 (2.0)   
Gleason Score   0.317 
   <7 944 (39.6) 901 (39.4)   
   7 953 (39.9) 896 (39.2)   
   >7 414 (17.4) 348 (15.2)   
   Missing 75 (3.1) 141 (6.2)   
Clinical Tumor Stage     0.446 
   Stage 1 1706 (71.5) 1649 (72.1)   
   Stage 2 574 (24.1) 514 (22.5)   
   Stage 3 58 (2.4) 62 (2.7)   
   Missing 48 (2.0) 61 (2.7)   
Active Treatment     <0.0001 
   No 393 (16.5) 567 (24.8)   
   Yes 1897 (79.5) 1620 (70.9)   
   Missing 96 (4.0) 99 (4.3)   
*For all other analyses, race is derived from survey data. 
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